Date: 2013-01-07
Type of information: Development agreement
Compound: FF284 (Debio 1347) and its companion diagnostic
Company: DebioPharm (Switzerland) Chugai (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease:
Details: Chugai and Debiopharm have entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology. Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialise FF284 in all countries worldwide including Japan. Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284. According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study.
Financial terms: In return for the license, Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.
Latest news:
